GLP-1 Drug Boom Fuels Secondary Surge in Male Cosmetic Procedures

A growing number of men in the U.S. are turning to cosmetic surgery and other aesthetic treatments after achieving significant weight loss with popular GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. This emerging trend is creating a new, lucrative market for plastic surgeons and companies developing related therapies for side effects such as sagging skin and hair loss.

A New Demographic for Clinics

Plastic surgeons report a notable increase in male clientele, many of whom are seeking to complete their physical transformation after shedding pounds. Dr. Sean Alemi, a New York-based facial plastic surgeon, told Reuters he has seen "a doubling in the number of male patients" over the last one to two years, with the majority coming in after weight loss, often from GLP-1 therapies.

This shift is reshaping the client base at aesthetic clinics, which have historically been dominated by women. According to the American Society of Plastic Surgeons (ASPS), men underwent 1.7 million cosmetic procedures in 2024, a 2.7% increase from the prior year. Procedures range from facelifts to address lost facial volume to tummy tucks and liposuction for removing loose skin.

The 'GLP-1 Effect' by the Numbers

The link between the rise in weight-loss drug prescriptions and male cosmetic procedures is supported by recent data. Dr. Bob Basu, president of the ASPS, stated that in the first quarter of 2026, nearly 70% of men who underwent surgical procedures had a history of GLP-1 use.

Ad

Other key figures illustrate the parallel trends:

• Men accounted for 28.3% of weight-loss drug prescriptions filled in 2026, a significant rise from 18.3% four years earlier, according to GoodRx data.
• Common procedures for men include eyelid surgery, liposuction, and tummy tucks, part of over 98,000 total surgeries performed on men in 2024, as reported by the ASPS.

Market Opportunities and Investment

The demand is creating new financial opportunities in the aesthetics sector, as these procedures are typically not covered by insurance and can be costly. Surgeon fees alone can range from $5,000 to $9,000 for male breast reduction and up to $19,000 for a facelift, according to the ASPS.

Beyond surgery, the market for treating related side effects like hair loss—a condition that can be triggered by the stress of rapid weight loss—is also expanding. This has attracted significant investment, including a $100 million funding round led by Eli Lilly in June for Absci, a company working to develop an antibody to address hair loss. Giovanni ​Di Napoli, CEO of Cosmo N.V., which is also developing hair loss treatments, noted to Reuters, "A man who used GLP-1 to look better, to lose weight, is also very interested in having his hair in good condition."